INAB
IN8bio, Inc.·Healthcare
1.39
2.797%(−0.04)
Market ClosedLast Updated: — ET
52W L: $1.1752W H: $5.82
INAB NEWS
globenewswire.com
Apr 3
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 11,800 shares of its common stock. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted outside of the Company's 2023 Equity Incentive Plan, with a grant date of April 1, 2026, as an inducement material to the new employees entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).
defenseworld.net
Mar 26
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)
IN8bio (NASDAQ: INAB - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation. Earnings and Valuation This table compares IN8bio and XBiotech"s
globenewswire.com
Mar 12
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI”) nearly doubling median progression-free survival (“mPFS”) to 13.0 months versus 6.6 months in a contemporaneous standard-of-care control cohort (+97%) Closed initial $20.1 million tranche of a private placement of up to $40.2 million in gross proceeds; net proceeds extend cash runway into the first half of 2027 and support advancement of the gamma-delta T cell engager (“TCE”) platform Continued advancement of gamma-delta T cell therapies and TCE pipeline across oncology and autoimmune diseases with multiple milestones expected in 2026 NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. “In 2025, we delivered meaningful progress financially and across our clinical γδ T cell therapy programs and our next-generation T cell engager platform,” said William Ho, co-founder and Chief Executive Officer of IN8bio.
globenewswire.com
Feb 24
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET. William Ho will be giving a company presentation highlighting IN8bio's latest achievements and upcoming milestones.
globenewswire.com
Feb 9
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately.
globenewswire.com
Feb 3
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity Conference Date: Thursday, February 5, 2026Time: 3:00 p.m.
